Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension
Abstract Background Prognosis of chronic thromboembolic pulmonary hypertension (CTEPH) has improved after the availability of balloon pulmonary angioplasty (BPA) and approved drugs. However, the clinical effects of cancer, which is one of the associated medical conditions of CTEPH, remain unclear. W...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-024-03460-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850282205287284736 |
|---|---|
| author | Hiroyuki Fujii Yu Taniguchi Yuichi Tamura Miki Sakamoto Sachiyo Yoneda Kenichi Yanaka Noriaki Emoto Ken-ichi Hirata Hiromasa Otake |
| author_facet | Hiroyuki Fujii Yu Taniguchi Yuichi Tamura Miki Sakamoto Sachiyo Yoneda Kenichi Yanaka Noriaki Emoto Ken-ichi Hirata Hiromasa Otake |
| author_sort | Hiroyuki Fujii |
| collection | DOAJ |
| description | Abstract Background Prognosis of chronic thromboembolic pulmonary hypertension (CTEPH) has improved after the availability of balloon pulmonary angioplasty (BPA) and approved drugs. However, the clinical effects of cancer, which is one of the associated medical conditions of CTEPH, remain unclear. We aimed to investigate prognosis in patients with CTEPH and comorbid cancer. Methods Between January 2011 and December 2022, data of 264 consecutive patients with CTEPH who were treated with pulmonary endarterectomy, BPA, or medical therapy were retrospectively analyzed. The patients were allocated, based on the comorbidity of cancer as of December 2022, into the cancer (n = 47) and non-cancer (n = 217) groups. In the cancer group, active and non-active cancers were identified in 30 (64%) and 17 (36%) patients, respectively. Results The baseline characteristics, hemodynamics, and treatments were similar between the groups. More than half of the cancer were diagnosed within two years before or after CTEPH diagnosis. Twenty-seven patients died during the study period. Among them, 13 (48%) and 7 (26%) died of cancer and right heart failure, respectively. The 5-year survival rate was lower in the cancer group than in the non-cancer group (67.8% vs. 94.5%, p < 0.001). In the active cancer group, the 5-year survival rate was also lower than that in the non-active cancer and non-cancer groups (52.0% vs. 99.5%, p < 0.001 and 52.0% vs. 92.3%, p < 0.001, respectively). Multivariate Cox hazard analysis revealed that hemodialysis (p < 0.001) and cancer (p < 0.001) were independently associated with poor survival. Conclusion Patients with CTEPH rarely die of right heart failure, even if hemodynamically severe at diagnosis in the modern management era. However, patients with CTEPH frequently have comorbid cancer, which may be a strong prognostic factor. |
| format | Article |
| id | doaj-art-ec186bffe01f4c8ea164e61edc938aee |
| institution | OA Journals |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-ec186bffe01f4c8ea164e61edc938aee2025-08-20T01:48:03ZengBMCBMC Pulmonary Medicine1471-24662025-01-012511810.1186/s12890-024-03460-5Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertensionHiroyuki Fujii0Yu Taniguchi1Yuichi Tamura2Miki Sakamoto3Sachiyo Yoneda4Kenichi Yanaka5Noriaki Emoto6Ken-ichi Hirata7Hiromasa Otake8Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicinePulmonary Hypertension Center, International University of Health and Welfare Mita HospitalDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of MedicineAbstract Background Prognosis of chronic thromboembolic pulmonary hypertension (CTEPH) has improved after the availability of balloon pulmonary angioplasty (BPA) and approved drugs. However, the clinical effects of cancer, which is one of the associated medical conditions of CTEPH, remain unclear. We aimed to investigate prognosis in patients with CTEPH and comorbid cancer. Methods Between January 2011 and December 2022, data of 264 consecutive patients with CTEPH who were treated with pulmonary endarterectomy, BPA, or medical therapy were retrospectively analyzed. The patients were allocated, based on the comorbidity of cancer as of December 2022, into the cancer (n = 47) and non-cancer (n = 217) groups. In the cancer group, active and non-active cancers were identified in 30 (64%) and 17 (36%) patients, respectively. Results The baseline characteristics, hemodynamics, and treatments were similar between the groups. More than half of the cancer were diagnosed within two years before or after CTEPH diagnosis. Twenty-seven patients died during the study period. Among them, 13 (48%) and 7 (26%) died of cancer and right heart failure, respectively. The 5-year survival rate was lower in the cancer group than in the non-cancer group (67.8% vs. 94.5%, p < 0.001). In the active cancer group, the 5-year survival rate was also lower than that in the non-active cancer and non-cancer groups (52.0% vs. 99.5%, p < 0.001 and 52.0% vs. 92.3%, p < 0.001, respectively). Multivariate Cox hazard analysis revealed that hemodialysis (p < 0.001) and cancer (p < 0.001) were independently associated with poor survival. Conclusion Patients with CTEPH rarely die of right heart failure, even if hemodynamically severe at diagnosis in the modern management era. However, patients with CTEPH frequently have comorbid cancer, which may be a strong prognostic factor.https://doi.org/10.1186/s12890-024-03460-5Chronic thromboembolic pulmonary hypertensionCancerPrognosisBalloon pulmonary angioplasty |
| spellingShingle | Hiroyuki Fujii Yu Taniguchi Yuichi Tamura Miki Sakamoto Sachiyo Yoneda Kenichi Yanaka Noriaki Emoto Ken-ichi Hirata Hiromasa Otake Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension BMC Pulmonary Medicine Chronic thromboembolic pulmonary hypertension Cancer Prognosis Balloon pulmonary angioplasty |
| title | Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| title_full | Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| title_fullStr | Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| title_full_unstemmed | Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| title_short | Association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| title_sort | association between the prognosis and comorbidity of active cancer in chronic thromboembolic pulmonary hypertension |
| topic | Chronic thromboembolic pulmonary hypertension Cancer Prognosis Balloon pulmonary angioplasty |
| url | https://doi.org/10.1186/s12890-024-03460-5 |
| work_keys_str_mv | AT hiroyukifujii associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT yutaniguchi associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT yuichitamura associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT mikisakamoto associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT sachiyoyoneda associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT kenichiyanaka associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT noriakiemoto associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT kenichihirata associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension AT hiromasaotake associationbetweentheprognosisandcomorbidityofactivecancerinchronicthromboembolicpulmonaryhypertension |